

Enantioselective Syntheses of 2-Alkyl-, 2,6-Dialkylpiperidines and Indolizidine Alkaloids Through Diastereoselective Mannich–Michael Reactions

Markus Weymann, Waldemar Pfengle, Dieter Schollmeyer, Horst Kunz*

Institut für Organische Chemie, Universität Mainz, D-55099, Mainz, Germany

Fax + 49(6131)394786; E-mail: hokunz@goofy.zdv.uni-mainz.de

Received 1 April 1997


Dedicated to Professor Waldemar Adam on the occasion of his 60th birthday

Aldimines of 2,3,4,6-tetra-*O*-pivaloyl- β -D-galactosylamine react with 1-methoxy-3-trimethylsilyloxybuta-1,3-diene in a Mannich–Michael condensation reaction sequence to give 2-substituted *N*-galactosyl-5,6-dehydropiperidin-4-ones **3** with high diastereoselectivity. The X-ray analysis of the 2-propyl derivative **3a** proved (*R*)-configuration of the major diastereomer and led to the correction of our earlier assignment of configuration for (–)-coniine hydrochloride **9a** obtained from this intermediate. Despite their low reactivity, these enaminones **3** can be converted into chiral 2,6-*cis*-disubstituted piperidinones **12** with high stereoselectivity by reaction with organocuprates in combination with hard electrophiles. Enantiomerically pure alkaloids such as (–)-dihydropinidine and gephyrotoxin **167B** have been synthesized according to this methodology.

Numerous natural products and drugs contain chiral nitrogen heterocycles as structural elements. A series of alkaloids belong to the class of 2-alkyl- and 2,6-dialkylpiperidines.¹ Because these compounds often exhibit marked pharmacological effects and new members of this class are continuously discovered in nature,² stereoselective syntheses of chiral piperidines are receiving increasing interest. Asymmetric syntheses of these compounds have been achieved by cyclizations of 1,5-dicarbonyl compounds³ of functionalized chiral amines,⁴ by nucleophilic addition reactions of *N*-alkyl- or *N*-acylpyridinium salts⁵ and by reactions of 1-methoxy-3-trimethylsilyloxybuta-1,3-diene (Danishefsky diene)⁶ with chiral imines.⁷ In an analogous manner, chiral chromium-carbonyl complexes of imines of aromatic aldehydes have recently been used for reactions with the Danishefsky diene.⁸

The aldimines **2** of tetra-*O*-pivaloyl- β -D-galactosylamine (**1**) used for enantioselective syntheses of 2-substituted piperidines gave high yields and high diastereoselectivities in their reactions with the Danishefsky diene.^{7a} In addition, the auxiliary can be recovered almost quantitatively after simple acidic cleavage of the *N*-glycosidic bond. It was revealed in more detailed investigations that the galactosyl imines **2** react with isoprene in the presence of zinc chloride via a concerted aza Diels–Alder reaction,^{7b} whereas the reaction with the Danishefsky diene proceeds via an initial Mannich reaction (Scheme 1).^{7a}

As a rule, the 2-substituted dehydropiperidinones **3** were formed with excellent diastereoselectivity. Pure diastereomers of the chiral piperidinone derivatives were obtained after simple recrystallization or flash chromatography. In order to assign the absolute configuration of compounds **3**, we converted **3a** into coniine^{7a} and **3b** into anabasine.^{7a,b} Since the hydrochloride of the obtained coniine showed a negative optical rotation, comparison with data reported in the literature⁹ implied the product to have the (*S*)-configuration.^{7a} However, this was in





Scheme 1

contradiction to the observed (*S*)-configuration of the anabasine formed in analogous conversion from **3b**^{7a,b} and also to other assignments of the configuration of coniine reported in the literature.^{3,4,5,7d,e}

Because all the assignments of the configuration of coniine reported in the literature themselves were based on the comparison of optical rotation values with that given in earlier reports,^{9,10} we searched for an independent unequivocal elucidation of the absolute configuration of the 2-alkylpiperidines synthesized according to Scheme 1. In one approach to this aim, dehydropiperidinones **3** are planned to be converted into 2,6-disubstituted piperidine alkaloids, although these enaminones **3** had shown marked resistance to reactions with strong nucleophiles like Grignard compounds or organocuprates. However, it can be stated beforehand, that the unambiguous clarification of the absolute configuration of the coniine formed from **3a** became possible when we succeeded in the isolation of suitable crystals of **3a** and their X-ray analysis (Figure 1).

The X-ray structural analysis (Figure 1) shows the coniine precursor **3a** to have (*R*)-configuration. These results disprove the data given for coniine hydrochloride in the literature,⁹ and therefore our earlier assignment of the structure of coniine hydrochloride formed from **3a** as well as that for a coniine produced in an analogous reaction sequence from imines of amino acid esters.^{7c} As a consequence, the interpretation of the diastereofacial differentiation occurring at the zinc complex **4** of the *N*-galactosyl butyraldimine has to be corrected (Figure 2).


The silyl dienol ether does not attack the imine at the *Re*-face occupied by the coordinated zinc as is the case

Figure 1. X-Ray Structure of **3a**.Figure 2. Proposed Mechanism of Stereoselective Mannich Reaction of 1-Methoxy-3-trimethylsiloxybuta-1,3-diene with *N*-Galactosyl Imines.

in a Strecker reaction of **2** with trimethylsilyl cyanide in chloroform.¹¹ Instead the attack proceeds at the sterically less shielded *Si*-face of the galactosyl imine-Lewis acid complex (Figure 2) as was also observed in the corresponding Ugi reactions¹² and reactions with allylsilanes and allylstannanes.¹³

The conversion of the precursors **3a** and **3b** into the alkaloids (*R*)-coniine and (*S*)-anabasine was carried out according to the preliminarily described reaction sequences.^{7a,b} Treatment of **3a** and **3b** with lithium tris-(*s*-butyl)borohydride¹⁴ in tetrahydrofuran at -78°C resulted in almost quantitative formation of the 2-substituted piperidinones **5a** and **5b**. Acidolytic cleavage of the *N*-glycosidic bond of **5a** gave the hydrochloride of (*R*)-2-propylpiperidin-4-one (**6**) in the form of a monohydrate which is obviously stabilized by an intramolecular hydrogen bridge (Scheme 2). The isolation of the free ketone **6** required codistillation with acetonitrile and lyophilization in high vacuum. It is interesting to note that the reaction of **6** with 1,2-ethanedithiol in the presence of boron trifluoride exclusively furnished the monothioacetal. It is resistant to dehydration and transformation into the corresponding dithiolane due to a transannular stabilization. Therefore, the dithiolanes **7** were formed from the *N*-galactosylpiperidinones **5** by reaction with ethane-1,2-dithiol and subsequently subjected to desulfurization

with Raney nickel to give the *N*-galactosylated alkaloids **8**. The yield of anabasine derivative **8b** is lower because of its persistent adsorption on nickel.




Scheme 2

The release of the enantiomerically pure alkaloids (*R*)-coniine (**9a**) and (*S*)-anabasine (**9b**) from the carbohydrate-linked precursors **8** was achieved by mild acidolysis with dilute hydrochloric acid in aqueous methanol (Scheme 2). The carbohydrate auxiliary was recovered almost quantitatively by simple extraction with pentane. Both alkaloids were isolated as their hydrochlorides, but for comparison of its analytical data with those reported in the literature,¹⁵ anabasine **9b** was converted into its *N*-(4-nitrobenzoyl) derivative **10**.


An alternative conversion of the enaminone **3a** into the *N*-galactosyl coniine **8a** consists of trapping the lithium enolate generated during reduction with lithium tris-(*s*-butyl)borohydride by *N,N*-bis(trifluoromethanesulfonyl)aniline¹⁶ and subsequent hydrogenation of the formed enol triflate **11** (Scheme 3).

The use of the chiral heterocycles **3** of now clarified configuration for further transformations failed at first because of the low reactivity of their vinylogous amide

structure. Even organolithium compounds did not attack the enaminone ring. With lower-order as well as with higher-order organocuprates only slow reactions occurred. After several days a conversion of at best 30 % was achieved. However, the formed products did not have the desired structure of 2,6-disubstituted piperidinones. Only the application of organocuprates in combination with hard electrophiles such as trimethylsilyl chloride¹⁷ (TMSCl) or boron trifluoride–diethyl ether complex¹⁸ resulted in 1,4-addition reactions to enaminones **3** and gave 2,6-*cis*-disubstituted piperidinones **12** in useful yields and high diastereoselectivity (Scheme 4, Table 1).





Scheme 3



Scheme 4

Table. Diastereoselective Synthesis of 2,6-Disubstituted Piperidinones **12** from *N*-Galactosyldehydropiperidinones **3**

Starting Materials		Product	Yield (%)	dr ^a
Ketone	R ¹ Cu-Complex			
3a	Me ₂ CuLi/TMSCl ^b	12a	71	> 10 : 1
3b	(EEOCH ₂ CH ₂ CH ₂) ₂ CuMgBr/TMSCl ^{b,c}	12b	82 ^d	3 : 1
3c	(<i>i</i> -C ₃ H ₇)Cu · BF ₃	12c	63	> 20 : 1
3d	[] Cu · BF ₃	12d	65 ^e	> 15 : 1
3e	[] Cu · BF ₃	12e	64 ^e	> 10 : 1

^a Diastereomeric ratio was determined by ¹H NMR spectroscopy.

^b Conjugated addition was followed by treatment with TBAF.

^c EE = 1-Ethoxyethyl.


^d CuBr · SMe₂ was used.

^e Cuprate formation was performed in the presence of substrate **3**.

The introduction of non-functionalized alkyl groups proceeded smoothly at –78°C in tetrahydrofuran with the lithium cuprate/TMSCl combination (**12a**) as well as with the Yamamoto complex¹⁸ formed from isopropylmagnesium bromide, copper iodide and boron trifluoride (**12c**). The 1,4-addition reaction of functionalized cuprate-BF₃ complexes to the 2-propyl-substituted enaminone **3a** was insufficient independent of the applied copper salt CuI or CuBr · SMe₂. In contrast, the same substrate **3a** effi-

ciently reacted with TMSCl and 3-(1-ethoxy)ethoxypyruplate obtained from the corresponding Grignard compound to yield the desired 2,6-disubstituted piperidine derivative **12b**. The stereoselectivity was only moderate. After both TMSCl-promoted reactions of **3a**, the primarily formed silyl enol ether was subsequently cleaved using tetrabutylammonium fluoride (TBAF) in tetrahydrofuran to furnish the piperidinone **12a** or **12b**, respectively. The 2-isopropyl- (**3c**) as well as the 2-aryldihydropyridinone **3d** reacted with functionalized organocuprate-BF₃ complexes generated in situ in the presence of the substrate to furnish the 2,6-disubstituted piperidinones **12d** and **12e** in good yield and high diastereoselectivity. These reactions illustrate the general applicability of this method for the stereoselective synthesis of 2,6-disubstituted piperidines.


Without further purification, the isolated 2-propyl-6-methylpiperidinone derivative **12a** was subjected to conversion into the dithiolane **13** and subsequent desulfurization using Raney nickel to give the *N*-galactosyl dihydropyridine **14** in an overall yield of 78 %. Treatment of **14** with hydrogen chloride in aqueous methanol resulted in the cleavage of the *N*-glycosidic bond. (–)-Dihydropyridine (**15**), which earlier had been synthesized by different strategies,^{3a,19} was isolated in high yield and enantiomerically pure form (Scheme 5). The scissioned carbohydrate auxiliary was recollectd almost quantitatively after extraction with diethyl ether.



Scheme 5

The side chain functionalized 2,6-disubstituted dihydropyridine **12b** was used for an enantioselective synthesis of gephyrotoxin 167B which belongs to the minor alkaloids of skin secretions of Central and South American frogs *Dendrobates pumilio*.²⁰ Up to now, enantioselective syntheses of the indolizidine alkaloid 167B had been achieved either using a non-recoverable auxiliary²¹ or in ex-chiral pool syntheses starting from optically active amino acids.²² Simultaneous acidic cleavage of the *N*-glycosidic bond and of the 1-ethoxyethyl protecting group gave 2-(3-hydroxypropyl)-6-propylpiperidinone (**16**) and the carbohydrate auxiliary, both isolated in high yield. According to its ¹H NMR spectrum, the crude

piperidinone **16** showed the same ratio of diastereomers (3:1) as was found for the *N*-glycosyl derivative **12b** (Scheme 6).



Scheme 6

The crude piperidinone **16** was subjected to an Appel reaction²³ with triphenylphosphine/carbon tetrachloride in acetonitrile in the presence of triethylamine which resulted in sequential nucleophilic substitution and cyclization in one step.²⁴ Surprisingly, only the pure *cis*-diastereomer **17** of the indolizidinone was isolated. It is possible that the corresponding *trans*-isomer has similar chromatographic properties as triphenylphosphine oxide and was separated together with this product during chromatography. However, it seems more likely that the *trans*-isomer is more resistant to substitution and cyclization. This conclusion is supported by the observation that amino alcohol was detectable by TLC even after a reaction time of 24 hours. After conversion of **17** into the dithiolane **18** and subsequent desulfurization using Raney nickel, enantiomerically pure (5*R*, 8*aR*)-gephyrotoxine 167B (**19**) was obtained without any additional purification.

Both enantioselective syntheses of alkaloids (5*R*, 8*aR*)-gephyrotoxine 167B (**19**) and (–)-dihydropinidine (**15**) show that the diastereoselective domino Mannich–Michael reaction of *N*-galactosyl imines **2** with silyldienol ethers of the Danishefsky diene-type in combination with a subsequent 1,4-addition reaction of the obtained dehydropiperidinones **3** with organocuprates in the presence of hard electrophiles, e.g., boron trifluoride or trimethylsilyl chloride, provide an efficient enantioselective access to pharmacologically interesting chiral heterocycles.³³ The clarification of the configuration of the coniine precursor **3a** by means of X-rays analysis ascertains the

stereochemical course of these reactions. The potential of these stereoselective syntheses is further extended by the fact that the corresponding *N*-(D-arabinosyl)imines allow the synthesis of the opposite enantiomers by application of the same sequence of reactions.²⁵

Reagents and solvents were distilled before use: THF, dioxane, and Et₂O were distilled from potassium/benzophenone ketyl. CH₂Cl₂ was distilled from CaH₂. Light petroleum ether refers to bp 60–80 °C. All reactions and distillations were carried out in flame-dried glassware under argon atmosphere.

TLC was performed on silica gel 60 F₂₅₄ (E. Merck, Darmstadt, Germany). Flash chromatography was carried out on silica gel MN 60 (0.04–0.063 mm), Macherey und Nagel, for chromatography under atmospheric pressure, silica gel 60 (0.06–0.2 mm) (Baker) was used. Analytical HPLC was carried out in MeOH/H₂O mixtures using a LKB 2150 unit equipped with diode array detection (LKB 2140). ¹H and ¹³C NMR spectra were recorded on a Bruker AC-200 or an Bruker AC-400 NMR spectrometer. Optical rotation values were measured with a Perkin-Elmer 241 polarimeter. FAB-MS-spectra were recorded on a Finnigan-MAT-95-spectrometer. Schiff bases **2** of commercially available amine **1** (Merck-Schuchard) were prepared according to known procedures.²⁶

N-Galactosyldehydropiperidinones **3**: General Procedure:

To a solution of glycosyl imine **2** (10 mmol) in THF (50 mL) was added a solution of ZnCl₂ (1.5 g, 11 mmol) in THF/CH₂Cl₂ (1:1, 11 mL) at –78 °C and stirred for 10 min. 1-Methoxy-3-trimethylsilyloxybuta-1,3-diene (2.5 mL, 12.5 mmol) was added. After stirring for 30 min, the mixture was allowed to warm up to –20 °C. After 24–48 h (TLC monitoring), the reaction was terminated by addition of 1 N HCl (10 mL). THF was evaporated in vacuo, THF (200 mL) was added, and the organic layer was separated, washed with satd aq NaHCO₃ (2 × 50 mL), 10% aq Titriplex®III (2 × 50 mL), and with brine, dried (MgSO₄), and concentrated to give the crude product which was purified by recrystallization or chromatography.

(2*R*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl-β-D-galactopyranosyl)-2-propyl-5,6-dehydropiperidin-4-one (**3a**):

Purification by chromatography (petroleum ether/EtOAc, 3:1); yield: 72% (based on amine **1**); mp 171 °C; [α]_D²² –73.5 (*c* = 1, CHCl₃); *R*_f 0.26 (petroleum ether/EtOAc, 2:1); diastereomeric ratio (dr) »15:1.

¹H NMR (200 MHz, CDCl₃): δ = 0.86 (t, 3 H, *J* = 7.2 Hz, propyl-CH₃), 1.08–1.50 (m, 38 H, Piv-CH₃, CH₂), 1.59 (m, 1 H, CH₂), 1.86 (m, 1 H, CH₂), 2.32 (d, 1 H, *J* = 16.5 Hz, CH₂C=O), 2.58 (dd, 1 H, *J* = 6.2, 16.6 Hz, CH₂C=O), 3.71 (m, 1 H, CHN), 3.92 (dd, 1 H, *J* = 6.5, 9.8 Hz, H-6a), 4.02 (dd, 1 H, *J* = 6.4, 6.1 Hz, H-5), 4.17 (dd, 1 H, *J* = 5.9, 9.7 Hz, H-6b), 4.54 (d, 1 H, *J* = 9.0 Hz, H-1), 4.92 (d, 1 H, *J* = 7.6 Hz, NCH=CH), 5.14 (dd, 1 H, *J* = 3.0, 10.1 Hz, H-3), 5.40 (d, 1 H, *J* = 2.9 Hz, H-4), 5.51 (dd, 1 H, *J* = 9.3, 9.8 Hz, H-2), 6.88 (d, 1 H, *J* = 7.7 Hz, NCH=CH).

¹³C NMR (100.6 MHz, CDCl₃): δ = 13.74 (propyl-CH₃), 18.88 (CH₂), 27.00, 27.10, 27.14 (Piv-CH₃), 32.97 (CH₂), 38.68, 38.74, 38.88, 39.04 (Piv-C_{quart}), 39.17 (CH₂C=O), 53.37 (CHN), 60.84 (C-6), 65.38, 66.56, 71.36, 72.95 (C-2, C-3, C-4, C-5), 91.57 (C-1), 100.07, 149.62 (CH=CH), 176.49, 176.99, 177.09, 177.68 (PivC=O), 192.02 (C=O).

C ₃₄ H ₅₅ NO ₁₀	calc.	C 64.03	H 8.69	N 2.20
(637.8)	found	64.23	8.73	2.00

X-ray Analysis of 3a: monoclinic, space group P2₁, *a* = 12.5889(7) Å, *b* = 10.5598(4) Å, *c* = 14.7355(5) Å, β = 96.900(5)°, *V* = 1944.7(2) Å³, *Z* = 2, ρ_{calc} = 1.089 g cm^{–3}, μ(CuKα) = 0.65 mm^{–1}, crystal dimensions = 0.64 × 0.160 × 0.160 mm, 8321 intensities were collected with 1.5° ≤ θ ≤ 75° at 298 K on a Enraf Nonius CAD4 diffractometer with graphite monochromated CuKα radiation (λ = 1.5418 Å), 7530 symmetry independent reflections (*R*_{int} = 0.033), no absorption correction, 5521 reflections with *I*(*s*(*F*)) > 4.0 were treated as observed. The structure was solved by direct methods (SIR-92).²⁷ Refinement on *F*² (ShelXL-93)²⁸ converged at *R*₁ = 0.0572, *wR*₂ = 0.1734

and goodness-of-fit = 1.032 (data to parameter ratio = 17), absolute configuration proved by measuring Friedel pairs and Flack²⁹ parameter 0.0(2).³⁴

(2*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-(3-pyridyl)-5,6-dehydropiperidin-4-one (**3b**):

Purification by flash chromatography (petroleum ether/EtOAc, 1:1); yield: 90%; mp 176°C (pentane); $[\alpha]_D^{20} + 19.6$ ($c = 3$, CHCl₃); R_f 0.25 (petroleum ether/EtOAc, 1:2); dr > 95:5.

¹H NMR (200 MHz, CDCl₃): δ = 1.07 (s, 9H, Piv-CH₃), 1.10 (s, 9H, Piv-CH₃), 1.13 (s, 9H, Piv-CH₃), 1.21 (s, 9H, Piv-CH₃), 2.58 (dd, 1H, $J = 5.6$, 16.5 Hz, CH₂C=O), 2.92 (dd, 1H, $J = 6.5$, 16.5 Hz, CH₂C=O), 3.66–3.86 (m, 3H, H-5, H-6a, H-6b), 4.48 (d, 1H, $J = 9.2$ Hz, H-1), 4.91 (t, 1H, $J = 6.0$ Hz, ArCHN), 5.07 (dd, 1H, $J = 3.0$, 10.0 Hz, H-3), 5.15 (d, 1H, $J = 7.9$ Hz, NCH=CH), 5.31 (d, 1H, $J = 3.0$ Hz, H-4), 5.56 (dd, 1H, $J = 9.8$, 9.4 Hz, H-2), 7.20 (m, 1H, Ar), 7.21 (d, 1H, $J = 7.9$ Hz, NCH=CH), 7.63, 8.51 (m, 1H, Ar).

¹³C NMR (100.6 MHz, CDCl₃): δ = 26.94, 26.97, 27.11 (Piv-CH₃), 38.57, 38.70, 38.90, 38.96 (Piv-C_{quart}), 42.94 (CH₂C=O), 55.90 (ArCHN), 60.68 (C-6), 65.47, 66.47, 71.11, 72.80 (C-2, C-3, C-4, C-5), 90.21 (C-1), 102.46 (CH=CH), 123.21, 134.12, 135.24, 148.33, 149.41 (Ar), 150.09 (CH=CH), 176.29, 176.92, 177.14, 177.50 (PivC=O), 190.19 (C=O).

C ₃₆ H ₅₂ N ₂ O ₁₀	calc.	C 64.27	H 7.79	N 4.16
(672.8)	found	64.23	7.86	3.97

(2*R*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-isopropyl-5,6-dehydropiperidin-4-one (**3c**):

Purification by chromatography (petroleum ether/EtOAc, 3:1); yield: 58% (based on amine **1**); $[\alpha]_D^{22} - 69.8$ ($c = 1$, CHCl₃); R_f 0.15 (petroleum ether/EtOAc, 3:1); dr 33.5:1 (HPLC).

¹H NMR (400 MHz, CDCl₃): δ = 0.87 (d, 6H, $J = 6.8$ Hz, CH₃), 1.06 (s, 9H, Piv-CH₃), 1.07 (s, 9H, Piv-CH₃), 1.12 (s, 9H, Piv-CH₃), 1.23 (s, 9H, Piv-CH₃), 2.23 (m, 1H, CHMe₂), 2.37 (dd, 1H, $J = 6.8$, 16.9 Hz, CH₂C=O), 2.56 (dd, 1H, $J = 7.3$, 16.8 Hz, CH₂C=O), 3.51 (m, 1H, CHN), 3.95 (m, 2H, H-5, H-6a), 4.12 (dd, 1H, $J = 5.6$, 9.2 Hz, H-6b), 4.57 (d, 1H, $J = 9.2$ Hz, H-1), 4.90 (d, 1H, $J = 7.7$ Hz, NCH=CH), 5.13 (dd, 1H, $J = 10.0$, 3.0 Hz, H-3), 5.36 (d, 1H, $J = 2.9$ Hz, H-4), 5.53 (dd, 1H, $J = 9.3$, 9.7 Hz, H-2), 6.97 (d, 1H, $J = 7.8$ Hz, NCH=CH).

¹³C NMR (100.6 MHz, CDCl₃): δ = 17.71, 19.63 (CH₃), 26.98, 27.08, 27.10 (Piv-CH₃), 31.76 (CHMe₂), 35.71 (CH₂C=O), 38.65, 38.72, 38.87, 39.03 (Piv-C_{quart}), 58.93 (CHN), 60.95 (C-6), 65.59, 66.56, 71.61, 72.78 (C-2, C-3, C-4, C-5), 90.98 (C-1), 100.58, 149.94 (CH=CH), 176.48, 176.98, 177.13, 177.72 (PivC=O), 192.48 (C=O).

C ₃₄ H ₅₅ NO ₁₀	calc.	C 64.03	H 8.69	N 2.20
(637.8)	found	63.82	8.56	2.12

(2*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-(4-cyanophenyl)-5,6-dehydropiperidin-4-one (**3d**):

Purification by chromatography (petroleum ether/EtOAc, 3:1); yield: 71%; mp 121°C; $[\alpha]_D^{22} + 22.2$ ($c = 1$, CHCl₃); R_f 0.44 (petroleum ether/EtOAc, 1:1); dr > 20:1.

¹H NMR (200 MHz, CDCl₃): δ = 1.09 (s, 9H, Piv-CH₃), 1.11 (s, 9H, Piv-CH₃), 1.15 (s, 9H, Piv-CH₃), 1.21 (s, 9H, Piv-CH₃), 2.54 (dd, 1H, $J = 4.6$, 16.5 Hz, CH₂C=O), 2.96 (dd, 1H, $J = 7.0$, 16.5 Hz, CH₂C=O), 3.75 (m, 3H, H-5, H-6a, H-6b), 4.54 (d, 1H, $J = 9.1$ Hz, H-1), 4.39 (dd, 1H, $J = 4.9$, 6.5 Hz, ArCHN), 5.11 (m, 2H, CH=CH, H-3), 5.32 (d, 1H, $J = 2.9$ Hz, H-4), 5.55 (dd, 1H, $J = 9.5$, 9.8 Hz, H-2), 7.21 (d, 1H, $J = 7.9$ Hz, CH=CH), 7.39 (d, 2H, $J = 8.3$ Hz, Ar), 7.57 (d, 2H, $J = 8.2$ Hz, Ar).

¹³C NMR (100.6 MHz, CDCl₃): δ = 26.88, 26.91, 27.06 (Piv-CH₃), 38.52, 38.65, 38.87 (Piv-C_{quart}), 42.67 (CH₂C=O), 57.09 (ArCHN), 60.58 (C-6), 65.48, 66.35, 70.92, 72.74 (C-2, C-3, C-4, C-5), 90.48 (C-1), 102.12 (CH=CH), 111.85, 118.14, 127.24, 132.23 (Ar), 145.05 (CN), 150.13 (CH=CH), 176.14, 176.87, 177.17, 177.46 (PivC=O), 189.84 (C=O).

C ₃₈ H ₅₂ N ₂ O ₁₀	calc.	C 65.50	H 7.52	N 4.02
(696.8)	found	65.52	7.53	3.87

Conversion of Enaminones **3** into the *N*-Glycosylpiperidinones **5**;

General Procedure:

To a solution of dehydropiperidinone **3** (10 mmol) in THF (90 mL) was added dropwise a 1 M THF solution of L-Selectride®¹⁴ at -78°C during 5 min. After conversion of the starting material (monitoring by TLC), the solution was warmed up to r.t., and the THF was evaporated in vacuo. The residue was dissolved in pentane (100 mL), washed with H₂O and dried (MgSO₄). Concentration of the organic layer in vacuo gave the crude product which was purified by flash chromatography.

(2*R*)-*N*-(2,3,4,6-Tetra-*O*-pivalyl- β -D-galactopyranosyl)-2-propylpiperidin-4-one (**5a**):

Yield: 95%; oil; $[\alpha]_D^{20} + 0.5$ ($c = 3$, CHCl₃); R_f 0.70 (petroleum ether/EtOAc, 2:1).

¹H NMR (400 MHz, CDCl₃): δ = 0.82 (t, 3H, $J = 7.2$ Hz, propyl-CH₃), 1.10–1.35 (m, 3H, CH₂), 1.43 (m, 1H, CH₂), 2.15 (m, 2H, CH₂), 2.47 (m, 1H, CH₂), 2.62 (dd, 1H, $J = 5.2$, 13.9 Hz, CH₂), 3.16 (m, 3H, CHN, CH₂), 3.89 (m, 2H, H-5, H-6a), 4.01 (dd, 1H, $J = 6.8$, 10.6 Hz, H-6b), 4.35 (d, 1H, $J = 9.1$ Hz, H-1), 5.11 (dd, 1H, $J = 3.1$, 10.1 Hz, H-3), 5.33 (d, 1H, $J = 3.0$ Hz, H-4), 5.42 (t, 1H, $J = 9.6$ Hz, H-2).

¹³C NMR (100.6 MHz, CDCl₃): δ = 13.90 (propyl-CH₃), 19.17 (CH₂), 27.03, 27.16 (Piv-CH₃), 35.53 (CH₂), 38.64, 38.70, 39.02 (Piv-C_{quart}), 41.63, 41.97, 46.58 (CH₂), 59.76 (CHN), 61.80 (C-6), 65.51, 67.26, 72.03 (C-2, C-3, C-4, C-5), 92.96 (C-1), 176.64, 177.00, 177.16, 177.77 (PivC=O), 209.66 (C=O).

C ₃₄ H ₅₇ NO ₁₀	calc.	C 63.83	H 8.98	N 2.19
(639.81)	found	63.81	9.01	2.28

(2*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-(3-pyridyl)piperidin-4-one (**5b**):

Yield: 96%; amorphous; $[\alpha]_D^{20} - 9.2$ ($c = 4$, CHCl₃).

¹H NMR (400 MHz, CDCl₃): δ = 2.46 (m, 2H, CH₂), 2.50 (dd, 1H, $J = 3.6$, 14.8 Hz, CH₂), 2.59 (dd, 1H, $J = 14.8$ Hz, CH₂), 2.97 (ddd, 1H, $J = 5.3$, 10.1, 12.4 Hz, NCH₂), 3.49 (m, 1H, H-5), 3.59 (ddd, 1H, $J = 5.4$, 9.3, 12.3 Hz, NCH₂), 3.82 (d, 1H, $J = 9.4$ Hz, H-1), 3.90 (dd, 1H, $J = 6.7$, 11.1 Hz, H-6a), 3.98 (dd, 1H, $J = 6.8$, 11.2 Hz, H-6b), 4.15 (dd, 1H, $J = 4.0$, 10.6 Hz, NCH), 4.87 (dd, 1H, $J = 3.1$, 10.0 Hz, H-3), 5.24 (d, 1H, $J = 2.5$ Hz, H-4), 5.44 (t, 1H, $J = 9.7$ Hz, H-2), 7.58 (m, 1H, Ar), 8.51 (d, 1H, $J = 1.9$ Hz, Ar), 8.59 (dd, 1H, $J = 1.5$, 4.7 Hz, Ar).

¹³C NMR (100.6 MHz, CDCl₃): δ = 27.00, 27.08, 27.16, 27.35 (Piv-CH₃), 38.67, 38.83, 39.01 (Piv-C_{quart}), 41.51, 43.46, 48.50 (CH₂), 61.40 (C-6), 61.57 (CHN), 65.05, 67.11, 71.67, 72.04 (C-2, C-3, C-4, C-5), 88.33 (C-1), 123.81, 135.25, 135.48, 149.49, 149.86 (Ar), 176.51, 177.04, 177.19, 177.74 (PivC=O), 206.79 (C=O).

C ₃₆ H ₅₄ N ₂ O ₁₀	calc.	C 64.08	H 8.07	N 4.15
(674.8)	found	64.12	8.01	4.21

Dithioacetals **7**: General Procedure:

To a suspension of piperidinone **5** (6.5 mmol), ethane-1,2-dithiol (0.7 mL, 8 mmol) and molecular sieves 5Å (5 g) in CH₂Cl₂ (30 mL) was added BF₃·OEt₂ (3.25 mL, 26 mmol) at 0°C. After 1 h the mixture was warmed up to r.t. and stirring was continued for additional 12 h. The suspension was diluted with CH₂Cl₂ (70 mL), filtered and extracted with satd aq NaHCO₃ (2 × 50 mL). The organic layer was washed with H₂O, dried (MgSO₄) and concentrated in vacuo. The crude product was purified by flash chromatography to yield **7** as a colorless amorphous solid.

(2*R*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-propylpiperidin-4-one Ethane-1,2-diyl Dithioacetal (**7a**):

Yield: 90%; mp 133°C; $[\alpha]_D^{20} - 18.6$ ($c = 2$, CHCl₃); R_f 0.49 (petroleum ether/EtOAc, 4:1).

¹H NMR (200 MHz, CDCl₃): δ = 0.88 (t, 3H, $J = 6.5$ Hz, propyl-CH₃), 1.07 (s, 9H, Piv-CH₃), 1.11 (s, 9H, Piv-CH₃), 1.14 (s, 9H, Piv-CH₃), 1.21 (s, 9H, Piv-CH₃), 1.17–1.46 (m, 4H, CH₂), 1.71 (dd, 1H, $J = 13.0$ Hz, CH₂), 1.84 (dd, 1H, $J = 3.6$, 14.8 Hz, CH₂), 2.02 (m, 2H, CH₂), 2.79 (m, 1H, CHN), 3.16 (m, 1H, NCH₂), 3.24 (m, 4H, SCH₂CH₂S), 3.80 (t, 1H, $J = 6.7$ Hz, H-5), 3.91 (dd, 1H, $J = 6.5$, 10.8 Hz, H-6a), 4.08 (dd, 1H, $J = 6.9$, 10.8 Hz, H-6b),

4.30 (d, 1 H, $J = 9.2$ Hz, H-1), 5.09 (dd, 1 H, 3.1, 10.0 Hz, H-3), 5.32 (d, 1 H, $J = 2.9$ Hz, H-4), 5.41 (t, 1 H, $J = 9.6$ Hz, H-2).

^{13}C NMR (50.3 MHz, CDCl_3): $\delta = 14.48$ (propyl- CH_3), 18.40 (CH_2), 27.06, 27.09, 27.21, 27.29 (Piv- CH_3), 34.74 (CH_2), 37.85 (CH_2), 38.66, 38.69, 38.72, 38.82 (Piv- C_{quart}), 39.06 (CH_2), 42.57, 44.23 ($\text{SCH}_2\text{CH}_2\text{S}$), 48.14 (CHN), 57.19 (NCH_2), 61.60 (C-6), 64.82 (CS_2), 66.98, 67.32, 71.80, 72.22 (C-2, C-3, C-4, C-5), 86.96 (C-1), 176.79, 176.94, 177.23, 177.86 (PivC=O).

$\text{C}_{36}\text{H}_{61}\text{NO}_9\text{S}_2$	calc.	C 60.39	H 8.59	N 1.96
(716.0)	found	60.45	8.59	1.89

(2*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-(3-pyridyl)-4-piperidin-4-one Ethane-1,2-diyl Dithioacetal (**7b**):

Yield: 92%; $[\alpha]_{\text{D}}^{20} -3.9$ ($c = 3$, CHCl_3); R_f 0.66 (petroleum ether/EtOAc, 1:1).

^1H NMR (400 MHz, CDCl_3): $\delta = 2.19$ (m, 4 H, CH_2), 2.83 (m, 1 H, NCH_2), 3.24 (m, 4 H, $\text{SCH}_2\text{CH}_2\text{S}$), 3.35 (m, 1 H, NCH_2), 3.43 (m, 1 H, H-5), 3.70 (d, 1 H, $J = 9.4$ Hz, H-1), 3.88 (dd, 1 H, $J = 7.1$, 11.2 Hz, H-6a), 3.92 (dd, 1 H, $J = 3.1$, 11.0 Hz, CHN), 4.03 (dd, 1 H, $J = 6.8$, 11.2 Hz, H-6b), 4.78 (dd, 1 H, $J = 3.1$, 10.0 Hz, H-3), 5.19 (d, 1 H, $J = 2.5$ Hz, H-4), 5.40 (t, 1 H, 9.7 Hz, H-2).

^{13}C NMR (100.6 MHz, CDCl_3): $\delta = 27.04$, 27.15, 27.20, 27.40 (Piv- CH_3), 38.68, 38.70, 38.80 (Piv- C_{quart}), 37.90, 39.03, 41.93, 44.15, 51.17 (CH_2), 61.15 (C-6), 61.55 (CHN), 66.09 (CS_2), 64.62, 67.19, 71.80, 72.01 (C-2, C-3, C-4, C-5), 87.85 (C-1), 123.65, 135.42, 136.50, 149.64, 149.89 (Ar), 176.62, 177.00, 177.09, 177.79 (PivC=O).

$\text{C}_{38}\text{H}_{58}\text{N}_2\text{O}_9\text{S}_2$	calc.	C 60.77	H 7.78	N 3.73
(751.0)	found	60.71	7.79	3.53

Reductive Desulfurization of **7** to give **8**: General Procedure:

To a solution of dithioacetal **7** (3 mmol) in *i*-PrOH (50 mL) was added Raney nickel (10 g). The resulting mixture was vigorously stirred under H_2 atmosphere at 70°C . After completion of the reaction (monitoring by TLC), the mixture was filtered through Celite and the filtrate concentrated in vacuo to yield pure **8** as a colorless amorphous solid.

(2*R*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-propylpiperidine (**8a**):

Yield: 98%; amorphous; $[\alpha]_{\text{D}}^{20} -2.7$ ($c = 2$, CHCl_3); R_f 0.57 (petroleum ether/EtOAc, 4:1).

^1H NMR (200 MHz, CDCl_3): $\delta = 0.88$ (t, 3 H, $J = 6.8$ Hz, propyl- CH_3), 1.08 (s, 9 H, Piv- CH_3), 1.13 (s, 9 H, Piv- CH_3), 1.15 (s, 9 H, Piv- CH_3), 1.18–1.58 (m, 19 H, Piv- CH_3 , CH_2), 2.44, 2.66, 3.12 (m, 3 H, CHN, NCH_2), 3.79 (t, 1 H, $J = 6.7$ Hz, H-5), 3.92 (dd, 1 H, $J = 6.5$, 10.9 Hz, H-6a), 4.08 (dd, 1 H, $J = 7.0$, 10.9 Hz, H-6b), 4.31 (d, 1 H, $J = 9.2$ Hz, H-1), 5.08 (dd, 1 H, $J = 3.1$, 10.0 Hz, H-3), 5.33 (d, 1 H, $J = 2.9$ Hz, H-4), 5.45 (t, 1 H, $J = 9.6$ Hz, H-2).

^{13}C NMR (50.3 MHz, CDCl_3): $\delta = 14.56$ (propyl- CH_3), 19.00, 23.85, 26.20 (CH_2), 27.28, 27.21, 27.10 (Piv- CH_3), 31.49, 34.78 (CH_2), 38.65, 38.70, 38.73, 39.06 (Piv- C_{quart}), 45.02 (NCH_2), 57.53 (CHN), 61.78 (C-6), 64.98, 67.54, 71.69, 72.52 (C-2, C-3, C-4, C-5), 89.30 (C-1), 176.84, 177.30, 177.91 (PivC=O).

$\text{C}_{34}\text{H}_{59}\text{NO}_9$	calc.	C 65.25	H 9.50	N 2.24
(625.8)	found	65.30	9.38	2.38

(2*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-(3-pyridyl)piperidine (**8b**):

Yield: 75%; amorphous; $[\alpha]_{\text{D}}^{20} -4.6$ ($c = 2$, CHCl_3).

^1H NMR (400 MHz, CDCl_3): $\delta = 1.80$ –1.25 (m, 6 H, CH_2), 2.58 (dd, 1 H, $J = 9.8$, 11.7 Hz, NCH_2), 3.30 (d, 1 H, $J = 11.6$ Hz, NCH_2), 3.41 (m, 1 H, H-5), 3.69 (dd, 1 H, $J = 2.3$, 11.3 Hz, CHN), 3.71 (d, 1 H, $J = 9.3$ Hz, H-1), 3.98 (dd, 1 H, $J = 7.0$, 11.2 Hz, H-6a), 3.99 (dd, 1 H, $J = 6.7$, 11.2 Hz, H-6b), 4.76 (dd, 1 H, $J = 3.1$, 10.0 Hz, H-3), 5.19 (d, 1 H, $J = 2.5$ Hz, H-4), 5.45 (t, 1 H, $J = 9.7$ Hz, H-2), 7.23 (dd, 1 H, $J = 4.9$, 7.5 Hz, Ar), 7.55 (m, 1 H, Ar), 8.47 (d, 1 H, $J = 1.7$ Hz, Ar), 8.52 (d, 1 H, $J = 1.6$ Hz, Ar).

^{13}C NMR (100.6 MHz, CDCl_3): $\delta = 27.02$, 27.12, 27.16, 27.36 (Piv- CH_3), 38.66, 38.77, 39.01 (Piv- C_{quart}), 24.87, 25.92, 35.74, 44.82 (CH_2), 61.67 (CHN), 62.08 (C-6), 64.56, 67.36, 71.71, 72.20 (C-2,

C-3, C-4, C-5), 88.55 (C-1), 123.52, 135.30, 138.26, 149.18, 149.76 (Ar), 176.61, 176.88, 177.12, 177.81 (PivC=O).

$\text{C}_{36}\text{H}_{56}\text{N}_2\text{O}_9$	calc.	C 65.43	H 8.54	N 4.24
(660.8)	found	65.36	8.68	4.21

N-Galactosylconiine (**8a**):

(6*R*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-6-propylpiperidine-3-en-4-yl Trifluoromethanesulfonate (**11**):

To a solution of dehydropiperidinone **3a** (1.28 g, 2.0 mmol) in THF (30 mL) was added dropwise a 1 M THF solution of *t*-Selectride[®]14 (5 mL, 2.5 equiv) at -78°C . After consumption of the starting material (TLC monitoring), *N,N*-bis(trifluoromethanesulfonyl)aniline¹⁶ (1.0 g, 3 mmol) was added under N_2 atmosphere. The stirring was continued for 1.5 h and the mixture was allowed warm up to r.t. The solvent was evaporated in vacuo, the residue was dissolved in Et_2O (50 mL), washed with brine, dried (MgSO_4) and concentrated in vacuo to afford crude **11** which was purified by chromatography (petroleum ether/EtOAc, 6:1); yield: 0.73 g (47%); colorless, amorphous solid; R_f 0.40 (petroleum ether/EtOAc, 5:1).

^1H NMR (400 MHz, CDCl_3): $\delta = 0.88$ (t, 3 H, $J = 7.1$ Hz, propyl- CH_3), 1.07 (s, 9 H, Piv- CH_3), 1.09 (s, 9 H, Piv- CH_3), 1.14 (s, 9 H, Piv- CH_3), 1.16–1.38 (m, 11 H, Piv- CH_3 , CH_2), 1.57 (m, 1 H, CH_2), 2.03 (d, 1 H, $J = 16.3$ Hz, CH_2), 2.55 (dd, 1 H, $J = 2.4$, 16.3 Hz, CH_2), 3.15 (m, 1 H, CHN), 3.41 (d, 1 H, $J = 17.6$ Hz, NCH_2), 3.57 (dd, 1 H, $J = 2.4$, 17.6 Hz, NCH_2), 3.83 (t, 1 H, $J = 6.7$ Hz, H-5), 3.89 (dd, 1 H, $J = 6.8$, 10.8 Hz, H-6a), 4.04 (dd, 1 H, $J = 6.6$, 10.8 Hz, H-6b), 4.20 (d, 1 H, $J = 9.2$ Hz, H-1), 5.09 (dd, 1 H, $J = 3.1$, 10.1 Hz, H-3), 5.34 (t, 1 H, $J = 9.6$ Hz, H-2), 5.35 (d, 1 H, $J = 3.0$ Hz, H-4), 5.66 (s, 1 H, $\text{CH}=\text{COTf}$).

^{13}C NMR (100.6 MHz, CDCl_3): $\delta = 14.06$ (propyl- CH_3), 19.90 (CH_2), 27.04, 27.15 (Piv- CH_3), 32.79, 33.65 (CH_2), 38.67, 38.72, 39.03 (Piv- C_{quart}), 41.76 (NCH_2), 55.42 (CHN), 61.55 (C-6), 65.47, 67.18, 71.90 (C-2, C-3, C-4, C-5), 92.63 (C-1), 116.15 ($\text{CH}=\text{COTf}$), 146.62 ($\text{CH}=\text{COTf}$), 176.65, 177.09, 177.18, 177.81 (PivC=O).

Conversion of **11 to **8**:** To the enol triflate **11** (0.66 g, 0.86 mmol) in MeOH (20 mL) were added Li_2CO_3 (100 mg) and Pd/C (5%, 46 mg). The mixture was vigorously stirred under a H_2 atmosphere (20 h). After filtration, the solvent was removed in vacuo and the remaining residue dissolved in Et_2O (50 mL). The organic layer was washed with brine (2×25 mL), dried (MgSO_4) and evaporated to dryness to yield pure **8a** (0.54 g, 98%) as a colorless solid.

Release of the Enantiomerically Pure Piperidines from the Carbohydrate Auxiliary; General Procedure:

The *N*-glycosylpiperidine or *N*-glycosylpiperidin-4-one (3 mmol) was dissolved in MeOH (30 mL) and treated with aq 1 N HCl (1.5 equiv). The solution was stirred at r.t. until completion of the reaction (monitoring by TLC). The solvent was evaporated in vacuo, the residue dissolved in pentane (60 mL) and the organic layer extracted with H_2O (3×30 mL). The carbohydrate auxiliary 2,3,4,6-tetra-*O*-pivaloyl- β -D-galactopyranose was recovered by concentration of the organic phase to dryness. To the combined aqueous layer was added Na_2CO_3 , the solution was extracted with Et_2O (3×60 mL). The organic layer was concentrated to a volume of 20 mL. A saturated solution of anhyd HCl in Et_2O (1 mL) was added and the hydrochloride of the piperidine derivative was isolated by filtration.

(2*R*)-2-Propylpiperidin-4-one Hydrochloride (**6**):

Yield: 95%; mp 147°C ; colorless crystals; $[\alpha]_{\text{D}}^{20} -23.4$ ($c = 2$, CHCl_3).

^1H NMR (400 MHz, CDCl_3): $\delta = 3.22$ (m, 1 H, CHN), 3.42 (m, 1 H, NCH_2), 3.72 (m, 1 H, NCH_2), 10.21 (s, 1 H, NH), 11.11 (s, 1 H, NH).

^{13}C NMR (100.6 MHz, CDCl_3): $\delta = 13.50$ (CH_3), 18.27, 34.92, 37.27, 34.91 (CH_2), 43.34 (NCH_2), 56.61 (CHN), 201.53 (C=O).

$\text{C}_8\text{H}_{16}\text{ClNO}$	calc.	C 54.08	H 9.08	N 7.88
(177.68)	found	53.56	9.02	7.59

(2*R*)-2-Propylpiperidine Hydrochloride (9a; Coniine Hydrochloride):

Yield: 97%; colorless crystals; mp 214–216°C; $[\alpha]_D^{20}$ –6.8 (c = 3.5, EtOH); $[\alpha]_D^{22}$ –6.8 (c = 0.6, MeOH) [Lit.³⁰ mp 221°C; Lit.^{3a} $[\alpha]_D^{22}$ –5.8 (c = 1.0, MeOH)].

¹H NMR (200 MHz, CDCl₃): δ = 0.90 (t, 3 H, J = 7.1 Hz, CH₃), 1.12–1.90 (m, 10 H, CH₂), 3.40 (m, 2 H, CHN, NCH₂), 3.40 (m, 1 H, NCH₂), 9.13 (s, 1 H, NH), 9.39 (s, 1 H, NH).

¹³C NMR (50.3 MHz, CDCl₃): δ = 13.65 (CH₃), 18.55, 22.17, 22.40, 28.15, 35.32 (CH₂), 44.73 (NCH₂), 57.11 (CHN).

(2*S*)-*N*-4-Nitrobenzoyl-2-(3-pyridyl)piperidine (10, *N*-4-Nitrobenzoylanabasine):

The release of anabasine hydrochloride **9b** from the carbohydrate auxiliary was achieved as described for **9a** by treatment of **8b** with 1 N aq HCl (2 equiv). Crude **9b** (3 mmol) was dissolved in CH₂Cl₂ (10 mL), treated with Et₃N (4 mL) and 4-nitrobenzoyl chloride (0.75 g, 4 mmol) and stirred at r.t. for 2 h. Additional CH₂Cl₂ (50 mL) was added, and the organic layer was washed with H₂O (2 × 100 mL). The organic layer was dried (MgSO₄) and the solvent was evaporated in vacuo. The crude product was purified by flash chromatography (EtOAc) to afford **10** (90%) as colorless crystals; mp 122°C; $[\alpha]_D^{20}$ –130.8 (c = 1.2, MeOH); R_f 0.45 (EtOAc) [Lit.¹⁵ mp 127–128°C; $[\alpha]_D$ –130.0 (c = 3, MeOH)].

Trimethylchlorosilane-Mediated Addition of Diorganocuprates to Enaminones 3; Typical Procedures:**(2*R*,6*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-propyl-6-methylpiperidin-4-one (12a):**

To a stirred suspension of CuI (1.43 g, 7.5 mmol) in THF (50 mL) at –34°C was added dropwise a 1.6 M Et₂O solution of MeLi (9.4 mL, 2 equiv). The mixture was stirred at –25°C for 1.5 h and then cooled to –78°C. To this mixture was added dropwise a solution of **3a** (3.0 g, 4.7 mmol) and TMSCl (1.9 mL, 15 mmol) in THF (100 mL) via a syringe. After 2 h at –78°C (monitoring by TLC), the reaction was terminated by the addition of 20% aq NH₄OH/NH₄Cl (50:50, 30 mL). Et₂O (300 mL) was added, and the organic layer separated. After washing with additional NH₄OH/NH₄Cl solution (50 mL), the organic layer was washed with brine and dried (MgSO₄). The solvent was evaporated in vacuo to yield the crude silyl enol ether as a colorless amorphous solid. It was dissolved in THF (15 mL) and treated with a 1 M THF solution of Bu₄NF (7 mL, 1.5 equiv) at 0°C. The resulting mixture was stirred at r.t. until completion of the reaction (monitoring by TLC). The mixture was concentrated in vacuo and diluted with Et₂O (100 mL). After washing with brine, the organic layer was dried (MgSO₄), and the solvent was removed in vacuo. Purification by chromatography (petroleum ether/EtOAc, 3:1) yielded **12a** (2.18 g, 71%) as a colorless amorphous solid; $[\alpha]_D^{22}$ 22.2 (c = 1.0, CHCl₃); R_f 0.55 (petroleum ether/EtOAc, 3:1); dr > 10:1.

¹H NMR (400 MHz, CDCl₃): δ = 0.84 (t, 3 H, J = 7.2 Hz, CH₃), 1.07–1.37 (m, 42 H, Piv-CH₃, CH₃, CH₂), 1.58 (m, 1 H, CH₂), 2.18 (d, 1 H, J = 15.4 Hz, CH₂), 2.24 (dd, 1 H, J = 6.6, 15.5 Hz, CH₂C=O), 2.57 (dd, 1 H, J = 5.9, 15.3 Hz, CH₂C=O), 2.73 (dd, 1 H, J = 6.8, 15.2 Hz, CH₂C=O), 3.32 (m, H, CHN), 3.75 (m, H, CHN'), 3.82–3.93 (m, 2 H, H-5, H-6a), 4.06 (m, 1 H, H-6b), 4.34 (d, 1 H, J = 9.2 Hz, H-1), 5.08 (dd, 1 H, J = 3.1, 9.9 Hz, H-3), 5.33 (d, 1 H, J = 3.0 Hz, H-4), 5.43 (t, 1 H, J = 9.6 Hz, H-2).

¹³C NMR (100.6 MHz, CDCl₃): δ = 13.87 (CH₃), 19.88 (CH₂), 24.36 (CH₃), 27.04, 27.17, 27.19 (Piv-CH₃), 38.67, 38.70, 39.01 (Piv-C_{quart}), 40.08 (CH₂), 44.37, 47.21 (CH₂C=O), 58.65 (CHN), 61.73 (C-6), 66.05, 67.28, 72.05, 72.44 (C-2, C-3, C-4, C-5), 94.28 (C-1), 176.64, 176.78, 177.24, 177.77 (PivC=O).

C ₃₅ H ₅₉ NO ₁₀	calc.	C 64.29	H 9.09	N 2.14
(653.9)	found	64.29	9.03	2.04

(2*S*,6*R*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2-(3-(1-ethoxyethoxy)propyl)-6-propylpiperidin-4-one (12b):

To magnesium (0.48 g, 20 mmol) in THF (6 mL) was added 3-bromopropyl (1-ethoxy)ethyl ether (4.4 g, 20 mmol) at r.t. The suspension was gently warmed until the reaction started and then imme-

diately cooled in an ice bath. The mixture was stirred for 1 h and diluted with THF (6 mL). The formation of the Grignard compound was complete after stirring for additional 2 h at <15°C. The resulting solution was added dropwise to a cooled (–70°C) suspension of CuBr·SMe₂ (1.85 g, 9.0 mmol) in THF (100 mL). After stirring for 2 h (–45°C), the red-brown suspension was cooled to –78°C. Slowly, a solution of **3a** (1.9 g, 3.0 mmol) and TMSCl (2.79 mL, 22 mmol) in THF (200 mL) was added and the mixture was stirred for 12 h. The workup was carried out as described for **12a**. The crude silyl enol ether thus obtained was converted to **12b** by treatment with a 1 M THF solution of Bu₄NF (4.5 mL, 1.5 equiv) at r.t. Isolation of **12b** was achieved according to the procedure described for **12a**. Chromatography (petroleum ether/EtOAc, 5:1) gave **12b**; yield: 1.9 g 82%; colorless oil; $[\alpha]_D^{22}$ –6.9 (c = 1.3, CHCl₃); R_f 0.37 (petroleum ether/EtOAc, 3:1); dr 3:1.

¹H NMR (200 MHz, CDCl₃): δ = 0.85 (t, 3 H, J = 7.1 Hz, CH₃), 1.08 (s, 9 H, Piv-CH₃), 1.13 (s, 9 H, Piv-CH₃), 1.14 (s, 9 H, Piv-CH₃), 1.15–1.70 (m, 23 H, Piv-CH₃, CH₂), 2.14–2.38 (m, 2 H, CH₂C=O), 2.61 (dd, 1 H, J = 5.8, 16.0 Hz, CH₂C=O), 2.69 (dd, 1 H, J = 6.8, 16.0 Hz, CH₂C=O), 3.24–3.70 (m, 6 H, OCH₂, CHN, CHN'), 3.90 (m, 2 H, H-6a, H-5), 4.07 (dd, 1 H, J = 9.3, 12.9 Hz, H-6b), 4.38 (d, 1 H, J = 9.2 Hz, H-1), 4.62 (q, 1 H, J = 5.4 Hz, OCHMeO), 5.08 (dd, 1 H, J = 2.9, 10.0 Hz, H-3), 5.36 (d, 1 H, J = 2.9 Hz, H-4), 5.43 (t, 1 H, J = 9.6 Hz, H-2).

¹³C NMR (100.6 MHz, CDCl₃): δ = 13.82, 15.22 (CH₃), 19.56 (CH₂), 19.74 (CH₃), 26.99, 27.01, 27.12 (Piv-CH₃), 27.94, 30.36, 34.41 (CH₂), 38.63, 38.68, 38.98, 39.94 (Piv-C_{quart}), 43.97, 44.33 (CH₂C=O), 61.61, 61.64 (CH₂, C-6), 66.30, 67.16, 71.96, 72.35 (C-2, C-3, C-4, C-5), 94.25 (C-1), 99.40 (OCHMeO), 176.55, 177.22, 177.50, 177.73 (PivC=O), 209.91 (C=O).

C ₄₁ H ₇₁ NO ₁₂	calc.	C 63.95	H 9.29	N 1.82
(770.0)	found	63.92	9.41	1.48

Conjugated Addition of R¹Cu·BF₃ Complexes to Enaminones 3; Typical Procedures:**(2*R*,6*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl- β -D-galactopyranosyl)-2,6-diisopropylpiperidin-4-one (12c):**

To a suspension of CuI (0.95 g, 5.0 mmol) in THF (15 mL) was added dropwise a 2 M Et₂O solution of isopropylmagnesium chloride (10 mL, 1 equiv) at –65°C. After 1.5 h the yellow mixture was cooled to –78°C. BF₃·OEt₂ (0.6 mL, 5.0 mmol) was added, and the mixture was stirred for 15 min. After dropwise addition of a solution of **3c** (0.64 g, 1.0 mmol) in (30 mL) through a syringe, the mixture was stirred at –78°C for 6 h. 20% aq NH₄OH/NH₄Cl (50:50, 15 mL) was added and the mixture was extracted with Et₂O (100 mL). The Et₂O solution was washed with NH₄OH/NH₄Cl solution (25 mL) and brine and dried (MgSO₄). The solvent was evaporated in vacuo and the residue purified by chromatography (petroleum ether/EtOAc, 4:1) to afford **12c** (0.43 g, 63%) as a colorless amorphous solid; $[\alpha]_D^{22}$ –41.4 (c = 1, CHCl₃); R_f 0.59 (petroleum ether/EtOAc, 2:1); dr > 20:1.

¹H NMR (200 MHz, CDCl₃): δ = 0.81 (d, 3 H, J = 6.6 Hz, CH₃), 0.85 (d, 3 H, J = 6.9 Hz, CH₃), 0.90 (d, 3 H, J = 6.9 Hz, CH₃), 0.91 (d, 3 H, J = 6.6 Hz, CH₃), 1.11–1.26 (m, 36 H, Piv-CH₃), 1.48 (m, 1 H, CHMe₂), 1.91 (m, 1 H, CHMe₂), 2.32 (d, 2 H, J = 8.6 Hz, CH₂C=O), 2.57 (dd, 1 H, J = 1.8, 17.3 Hz, CH₂C=O), 2.86 (dd, 1 H, J = 5.7, 17.3 Hz, CH₂C=O), 3.00 (m, 1 H, CHN), 3.20 (ddd, 1 H, J = 4.2, 8.4, 17.0 Hz, CHN'), 3.84–3.95 (m, 2 H, H-5, H-6a), 4.09 (dd, 1 H, J = 9.3, 12.8 Hz, H-6b), 4.50 (d, 1 H, J = 9.2 Hz, H-1), 5.05 (dd, 1 H, J = 2.8, 9.4 Hz, H-3), 5.29 (d, 1 H, J = 2.3 Hz, H-4), 5.33 (t, 1 H, J = 9.3 Hz, H-2).

¹³C NMR (100.6 MHz, CDCl₃): δ = 16.50, 19.76, 20.08, 21.07 (CH₃), 27.04, 27.08, 27.20, 27.25 (Piv-CH₃), 31.67, 34.06 (CHMe₂), 37.85 (CH₂C=O), 38.71, 38.78, 38.86, 39.06 (Piv-C_{quart}), 42.59 (CH₂C=O), 58.24, 61.32 (CHN, CHN'), 61.62 (C-6), 67.25, 67.35, 77.97, 73.86 (C-2, C-3, C-4, C-5), 93.19 (C-1), 176.43, 176.66, 177.56, 177.77 (PivC=O), 210.86 (C=O).

C ₃₇ H ₆₃ NO ₁₀	calc.	C 65.17	H 9.31	N 2.05
(681.9)	found	64.98	9.42	2.00

(2*R*,6*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl-β-*D*-galactopyranosyl)-2-(4-cyanophenyl)-6-[2-(1,3-dioxolan-2-yl)ethyl]piperidin-4-one (**12e**):

To a suspension of magnesium (0.18 g, 7.5 mmol) in THF (10 mL) was added 2-(2-bromoethyl)-1,3-dioxolane (0.84 mL, 7.0 mmol) at r.t. The suspension was gently warmed until the reaction started and then immediately cooled in an ice bath. The mixture was stirred for 2.5 h keeping the temperature below 10 °C. The resulting Grignard reagent was added dropwise to a cooled (−78 °C) suspension of CuI (1.33 g, 7 mmol) and enaminone **3d** (0.7 g, 1.0 mmol) in THF (100 mL). Within 1 h, the vigorously stirred suspension was allowed to warm up to −55 °C. After cooling to −78 °C, BF₃·OEt₂ (1.84 mL, 15 mmol) was added and the stirring was continued for 14 h. Workup and purification was conducted as described for **12c**; yield: 0.51 g (64 %); amorphous; [α]_D²² −34.1 (*c* = 0.25, CHCl₃); *R*_f 0.16 (petroleum ether/EtOAc, 3:1); dr >10:1.

¹H NMR (200 MHz, CDCl₃): δ = 1.02–1.27 (m, 36 H, Piv-CH₃), 1.34–1.61 (m, 4 H, CH₂), 2.49–2.61 (m, 3 H, CH₂C=O, CH₂C=O'), 2.89 (dd, 1 H, *J* = 5.4, 16.9 Hz, CH₂C=O'), 3.62 (m, 1 H, AlkylCHN), 3.72–3.96 (m, 6 H, OCH₂CH₂O, H-6a, H-5), 4.07 (d, 1 H, *J* = 9.6 Hz, H-1), 4.14 (dd, 1 H, *J* = 7.0, 11.0 Hz, H-6b), 4.63 (dd, 1 H, *J* = 4.7, 11.6 Hz, ArCHN), 4.77 (t, 1 H, *J* = 2.7, 4.4 Hz, OCHO), 4.85 (dd, 1 H, *J* = 2.9, 10.5 Hz, H-3), 5.28 (d, 1 H, *J* = 2.7 Hz, H-4), 5.50 (t, 1 H, *J* = 9.6 Hz, H-2), 7.44 (d, 2 H, *J* = 8.3 Hz, Ar), 7.63 (d, 2 H, *J* = 8.2 Hz, Ar).

¹³C NMR (100.6 MHz, CDCl₃): δ = 27.00, 27.12, 27.18, 27.34 (Piv-CH₃), 30.90, 33.73 (CH₂), 38.65, 38.96 (Piv-C_{quart}), 42.59, 46.39 (CH₂C=O, CH₂C=O'), 51.04 (AlkylCHN), 59.05 (ArCHN), 61.38 (C-6), 64.66, 64.75 (OCH₂CH₂O), 65.68, 67.15, 72.15, 72.80 (C-2, C-3, C-4, C-5), 91.13 (C-1), 103.96 (OCHO), 111.97, 118.32, 128.20, 132.56 (Ar), 147.97 (CN), 176.44, 176.52, 177.28, 177.67 (PivC=O), 207.44 (C=O).

C ₄₃ H ₆₂ N ₂ O ₁₂	calc.	C 64.64	H 7.82	N 3.51
(799.0)	found	63.95	7.80	3.29

The compound contained traces of inorganic material.

(2*R*,6*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl-β-*D*-galactopyranosyl)-2-*isopropyl*-6-[2-(1,3-dioxolan-2-yl)ethyl]piperidin-4-one (**12d**):

Piperidinone **12d** was prepared from **3c** (0.64 g, 1 mmol) in close analogy to the synthesis of **12e**; yield: 0.48 g (65 %); amorphous; [α]_D²² −27.8 (*c* = 0.35, CHCl₃); *R*_f 0.35 (petroleum ether/EtOAc, 3:1); dr >15:1.

¹H NMR (200 MHz, CDCl₃): δ = 0.80–0.89 (m, 6 H, CH₃), 1.09 (s, 9 H, Piv-CH₃), 1.13 (s, 9 H, Piv-CH₃), 1.15 (s, 9 H, Piv-CH₃), 1.24 (s, 9 H, Piv-CH₃), 1.33–1.85 (m, 5 H, CH₂, CHMe₂), 2.38 (m, 3 H, CH₂C=O, CH₂C=O'), 2.76 (dd, 1 H, *J* = 6.1, 17.2 Hz, CH₂C=O), 3.12 (m, 1 H, CHN), 3.45 (m, 1 H, CHN'), 3.74–3.94 (m, 7 H, OCH₂CH₂O, H-6a, H-6b, H-5), 4.37 (d, 1 H, *J* = 9.3 Hz, H-1), 4.79 (t, 1 H, *J* = 3.8 Hz, OCHO), 5.06 (dd, 1 H, *J* = 2.7, 9.8 Hz, H-3), 5.32 (d, 1 H, *J* = 2.6 Hz, H-4), 5.48 (t, 1 H, *J* = 9.5 Hz, H-2).

¹³C NMR (50.3 MHz, CDCl₃): δ = 16.91, 19.82 (CH₃), 27.02, 27.09, 27.18, 27.25 (Piv-CH₃), 31.45 (CHMe₂), 31.69, 33.08 (CH₂), 38.50, 38.68, 38.74, 39.02 (Piv-C_{quart}), 43.35 (CH₂C=O), 51.55 (CHN), 61.51 (C-6), 62.10 (CHN'), 64.73, 64.80 (OCH₂CH₂O), 66.02, 67.22, 71.98, 72.90 (C-2, C-3, C-4, C-5), 93.15 (C-1), 104.20 (OCHO), 176.67, 177.42, 177.79 (PivC=O), 210.63 (C=O).

C ₃₉ H ₆₅ NO ₁₂	calc.	C 63.31	H 8.85	N 1.89
(739.9)	found	63.33	8.85	1.89

(−)-Dihydropinidine Hydrochloride (**15**):

(2*R*,6*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl-β-*D*-galactopyranosyl)-2-*propyl*-6-methylpiperidin-4-one Ethane-1,2-diyl Dithioacetate (**13**):

To a suspension of piperidinone **12a** (1 g, 1.53 mmol) and ethane-1,2-dithiol (0.25 mL, 3 mmol) in CH₂Cl₂ (10 mL) was added dropwise BF₃·OEt₂ (0.94 mL, 5 equiv) at 0 °C. After 1 h, the mixture was warmed up to r.t. and the stirring was continued for 24 h. The suspension was diluted with CH₂Cl₂ (20 mL) and washed with satd aq NaHCO₃ (2 × 20 mL). The organic layer was washed with H₂O, dried (MgSO₄) and concentrated in vacuo. The crude product was purified by chromatography (petroleum ether/EtOAc, 8:1) to yield

13 (0.91 g, 81 %) as a colorless amorphous solid; [α]_D²² 4.9 (*c* = 1.2, CHCl₃); *R*_f 0.55 (petroleum ether/EtOAc, 5:1).

¹H NMR (400 MHz, CDCl₃): δ = 0.91 (t, 3 H, *J* = 7.2 Hz, CH₃), 1.08–1.29 (m, 39 H, Piv-CH₃, CH₃), 1.32–1.42 (m, 4 H, CH₂), 1.92–2.12 (m, 4 H, CH₂), 2.85 (m, 1 H, CHN), 3.09 (m, 1 H, CHN'), 3.24 (m, 4 H, SCH₂CH₂S), 3.84 (t, 1 H, *J* = 6.8 Hz, H-5), 3.94 (dd, 1 H, *J* = 6.6, 10.8 Hz, H-6a), 4.11 (dd, 1 H, *J* = 7.2, 10.9 Hz, H-6b), 4.41 (d, 1 H, *J* = 9.5 Hz, H-1), 4.96 (dd, 1 H, *J* = 3.1, 9.8 Hz, H-3), 5.36 (d, 1 H, *J* = 3.0 Hz, H-4), 5.53 (t, 1 H, *J* = 9.6 Hz, H-2).

¹³C NMR (100.6 MHz, CDCl₃): δ = 14.21 (CH₃), 19.97 (CH₂), 21.83 (CH₃), 27.10, 27.14, 27.18, 27.32 (Piv-CH₃), 38.57, 38.72, 38.96 (Piv-C_{quart}), 49.75 (CH₂), 59.24 (CHN), 61.72 (C-6), 67.44, 67.84, 72.44, 73.01 (C-2, C-3, C-4, C-5), 88.36 (C-1), 176.84, 177.40, 177.90 (PivC=O).

C ₃₇ H ₆₃ NO ₉ S ₂	calc.	C 60.88	H 8.70	N 1.92
(730.0)	found	60.87	8.76	1.86

(2*R*,6*S*)-*N*-(2,3,4,6-Tetra-*O*-pivaloyl-β-*D*-galactopyranosyl)-2-*propyl*-6-methylpiperidine (**14**):

N-Glycosyldihydropinidine **14** was prepared similar to **8** starting from **13** (0.74 g, 1 mmol); yield: 0.61 g (96 %); amorphous; [α]_D²² 10.6 (*c* = 0.7, CHCl₃); *R*_f 0.61 (petroleum ether/EtOAc, 5:1).

¹H NMR (400 MHz, CDCl₃): δ = 0.84 (t, 3 H, *J* = 7.3 Hz, CH₃), 1.07–1.49 (m, 45 H, Piv-CH₃, CH₃, CH₂), 1.66 (m, 4 H, CH₂), 2.93 (m, 1 H, CHN), 3.15 (m, 1 H, CHN'), 3.81 (t, 1 H, *J* = 6.8 Hz, H-5), 3.90 (dd, 1 H, *J* = 6.7, 10.9 Hz, H-6a), 4.07 (dd, 1 H, *J* = 6.9, 10.9 Hz, H-6b), 4.22 (d, 1 H, *J* = 9.3 Hz, H-1), 5.04 (dd, 1 H, *J* = 3.2, 9.9 Hz, H-3), 5.32 (d, 1 H, *J* = 2.8 Hz, H-4), 5.43 (t, 1 H, *J* = 9.5 Hz, H-2).

¹³C NMR (100.6 MHz, CDCl₃): δ = 14.34 (CH₃), 15.23, 21.61 (CH₂), 22.27 (CH₃), 27.08, 27.14, 27.30 (Piv-CH₃), 28.49, 31.56 (CH₂), 38.36, 38.67, 38.99 (Piv-C_{quart}), 62.06 (C-6), 65.65, 67.52, 71.54, 72.81 (C-2, C-3, C-4, C-5), 96.48 (C-1), 176.67, 176.84, 177.29, 177.94 (PivC=O).

C ₃₅ H ₆₁ NO ₉	calc.	C 65.70	H 9.61	N 2.19
(639.9)	found	65.70	9.51	2.13

(−)-(2*R*,6*S*)-2-Propyl-6-methylpiperidine Hydrochloride [**15**, (−)-Dihydropinidine Hydrochloride]:

The release of **15** from the carbohydrate auxiliary was carried out as described for **9**, starting from **14** (0.50 g, 0.86 mmol); yield: 92 %; colorless crystals; mp 206–208 °C; [α]_D²² −11.1 (*c* = 1.0, EtOH) [Lit.³¹ mp 215–220 °C; Lit.^{19c}, [α]_D²² −11.6 (*c* = 1.03, EtOH)].

¹H NMR (200 MHz, CDCl₃): δ = 0.80 (t, 3 H, *J* = 7.1 Hz, CH₃), 1.05–1.92 (m, 10 H, CH₂), 1.44 (d, 3 H, *J* = 5.6 Hz, CH₃), 2.81 (m, 1 H, CHN), 3.00 (m, 1 H, CHN'), 8.84 (s, 1 H, NH), 9.14 (s, 1 H, NH).

¹³C NMR (50.6 MHz, CDCl₃): δ = 13.61 (CH₃), 18.68, 19.33, 22.83, 27.41, 30.56, 35.09 (CH₂, CH₃), 54.37, 58.22 (CHN, CHN').

These data are in agreement with the spectra reported in the literature.³²

Gephyrotoxine **167B** (**19**):

(2*S*,6*R*)-2-(3-Hydroxypropyl)-6-propylpiperidin-4-one (**16**):

To a solution of *N*-glycosylpiperidin-4-one **12b** (2.0 g, 2.6 mmol) in MeOH (80 mL) was added 1 N aq HCl (5.5 mL). The mixture was stirred at r.t. until completion of the reaction (monitoring by TLC). The solvent was evaporated in vacuo, the residue dissolved in Et₂O (80 mL) and washed with H₂O (5 × 20 mL). The carbohydrate auxiliary was recovered by concentration of the organic phase. The combined aqueous solution was adjusted to pH 10 by addition of Na₂CO₃, stirred for 20 min and extracted with CH₂Cl₂ (3 × 50 mL). The combined organic layer was dried (Na₂SO₄) and evaporated to dryness in vacuo to afford crude **16** (87 %) as a pale yellow oil; yield: 87 %; dr 3:1.

major diastereomer:

¹H NMR (200 MHz, CDCl₃): δ = 0.87 (t, 3 H, *J* = 6.8 Hz, CH₃), 1.29–1.71 (m, 8 H, CH₂), 1.98 (dd, 1 H, *J* = 12.0, 14.0 Hz, CH₂C=O), 2.10 (dd, 1 H, *J* = 13.2, 13.4 Hz, CH₂C=O), 2.34 (m, 1 H, CH₂C=O), 2.44 (dd, 1 H, *J* = 4.9, 14.9 Hz, CH₂C=O), 2.82

(m, 1 H, CHN), 3.08 (m, 2 H, OH, NH), 3.25 (m, 1 H, CHN'), 3.57 (m, 2 H, CH₂).

¹³C NMR (100.6 MHz, CDCl₃): δ = 13.90 (CH₃), 18.86, 29.69, 34.97, 39.08 (CH₂), 48.38, 48.62 (CH₂C=O), 56.35 (CHN), 56.69 (CHN'), 62.50 (CH₂), 208.77 (C=O).

minor diastereomer:

¹³C NMR (100.6 MHz, CDCl₃): δ = 13.81 (CH₃), 19.17, 30.06, 32.86, 36.91 (CH₂), 47.78, 48.46 (CH₂C=O), 52.30 (m, 1 H, CHN), 52.78 (m, 1 H, CHN'), 62.50 (CH₂), 209.02 (C=O).

(5*R*,8*aS*)-5-Propyloctahydroindolizidin-7-one (**17**):

A solution of Et₃N (0.31 mL, 2.2 mmol) in CCl₄ (0.31 mL, 3.2 mmol) was added to crude **16** (0.43 g, 2.15 mmol) dissolved in MeCN (5 mL). The resulting solution was cooled to 0 °C, and Ph₃P (0.68 g, 2.0 mmol) was added. After 45 min the mixture was allowed to warm up to r.t. and the stirring was continued for 22 h. After addition of satd aq NaHCO₃ (20 mL) and Et₂O (80 mL), the separated organic layer was washed with brine and dried (Na₂SO₄). The solvent was evaporated in vacuo and the residue purified by chromatography (petroleum ether/EtOAc, 1:2) to afford **17** (0.25 g, 64%) as a pale yellow oil; [α]_D²² -20.4 (*c* = 2.2, CHCl₃); *R*_f 0.15 (petroleum ether/EtOAc, 1:2).

¹H NMR (200 MHz, CDCl₃): δ = 0.84 (t, 3 H, *J* = 7.1 Hz, CH₃), 1.10–1.94 (m, 8 H, CH₂), 1.99–2.44 (m, 7 H, NCH₂, NCH, CH₂C=O), 3.20 (dt, 1 H, *J* = 2.4, 8.4 Hz, NCH').

¹³C NMR (50.3 MHz, CDCl₃): δ = 14.17 (CH₃), 18.07, 21.32, 30.68, 36.94 (CH₂), 45.51, 47.04 (CH₂C=O), 50.12 (NCH₂), 60.90, 63.81 (NCH, NCH'), 209.38 (C=O).

FAB-MS (pos.; NBA): *m/z* = 182.3 (M + H⁺, 100%).

(5*R*,8*aS*)-5-(Propyl)octahydroindolizidin-7-one Ethane-1,2-diyl Dithioacetate (**18**):

A solution of indolizidinone **17** (0.2 g, 1.1 mmol) and ethane-1,2-dithiol (0.2 mL, 2.4 mmol) in CH₂Cl₂ (8 mL) was cooled to 0 °C. BF₃·OEt₂ (0.18 mL, 1.43 mmol) was added. After 30 min the mixture was warmed up to r.t. and stirred for an additional 12 h. The suspension was diluted with CH₂Cl₂ (30 mL), filtered and washed with satd aq NaHCO₃ (2 × 20 mL) and brine, dried (Na₂SO₄) and concentrated in vacuo. The crude product was purified by chromatography (petroleum ether/EtOAc, 1:1) to yield **18** (0.21 g, 74%) as a colorless oil; [α]_D²² -54.8 (*c* = 1.2, CHCl₃); *R*_f 0.44 (petroleum ether/EtOAc, 1:2).

¹H NMR (200 MHz, CDCl₃): δ = 0.84 (t, 3 H, *J* = 6.7 Hz, CH₃), 1.12–1.86 (m, 10 H, CH₂), 1.92–2.22 (m, 5 H, NCH₂, NCH, CH₂), 3.15 (dt, 1 H, *J* = 2.8, 8.5 Hz, NCH'), 3.23 (s, 4 H, SCH₂CH₂S).

¹³C NMR (50.3 MHz, CDCl₃): δ = 14.35 (CH₃), 18.68, 20.79, 29.94, 36.24, 37.72, 39.10 (CH₂), 47.30, 47.40 (SCH₂CH₂S), 50.55 (NCH₂), 61.80, 63.84 (NCH, NCH'), 66.83 (CS₂).

FAB-MS (pos.; NBA): *m/z* (%) = 258.6 (M + H⁺, 100%), 214.5 (M - C₃H₇⁺, 35.1%).

C ₁₃ H ₂₃ NS ₂	calc.	C 60.65	H 9.00	N 5.44
(257.5)	found	59.99	9.06	5.29

(5*R*,8*aR*)-5-(Propyl)octahydroindolizidine (**19**, Gephyrotoxine 167*B*):

Desulfurization of **18** (0.1 g, 0.388 mmol) was carried out as described for **8**; yield: 88%; pale yellow and volatile oil; [α]_D²² -99.2 (*c* = 0.3, hexane) [Lit.^{22a} [α]_D²⁰ -106.3 (*c* = 0.8, hexane)].

¹H NMR (200 MHz, CDCl₃): δ = 0.86 (t, 3 H, *J* = 6.9 Hz, CH₃), 1.02–1.47 (m, 7 H, CH₂), 1.49–2.02 (m, 10 H, NCH₂, NCH, CH₂), 3.22 (dt, 1 H, *J* = 2.3, 8.5 Hz, NCH').

¹³C NMR (100.6 MHz, CDCl₃): δ = 14.51 (CH₃), 19.18, 20.40, 24.68, 30.52, 30.80, 30.91, 36.86 (CH₂), 51.46 (NCH₂), 63.72, 65.08 (NCH, NCH').

These data are in agreement with the spectra reported in the literature.^{22a}

This work was supported by the Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie and by the Fonds der Chemischen Industrie. M. W. and W. P. are grateful for stipends of the Fonds der Chemischen Industrie.

- (1) Daly, J. W.; Garrato, H. M.; Spande, T. F. In *Alkaloids*; Cordell, G. A., Ed.; Academic: San Diego, 1993; Vol. 43, pp 185–288.
- (2) (a) Kobayashi, J.; Naitoh, K.; Doi, Y.; Deki, K.; Ishibashi, M. *J. Org. Chem.* **1995**, *60*, 6941.
(b) Toyooka, N.; Yotsui, Y.; Yoshida, Y.; Momose, T. *J. Org. Chem.* **1996**, *61*, 4882.
- (3) (a) Guerrier, L.; Royer, J.; Grierson, D. S.; Husson, H.-P. *J. Am. Chem. Soc.* **1983**, *105*, 7754.
(b) Yue, C.; Royer, J.; Husson, H.-P. *J. Org. Chem.* **1990**, *55*, 1140.
(c) Freville, S.; Celerier, J. P.; Thuy, V. M.; Lhomme, G. *Tetrahedron: Asymm.* **1995**, *6*, 2651.
- (4) (a) Enders, D.; Tiebes, J. *Liebigs Ann. Chem.* **1993**, 173.
(b) Oppolzer, W.; Bochet, C. G.; Merifield, E. *Tetrahedron Lett.* **1994**, *35*, 7015.
(c) Amat, M.; Llor, N.; Bosch, J. *Tetrahedron Lett.* **1994**, *35*, 2223.
(d) Akiyama, E.; Hiram, M. *Synlett* **1996**, 100.
(e) Thank, G. V.; Célèrier, J.-P.; Lhomme, G. *Tetrahedron: Asymm.* **1996**, *7*, 2211.
- (5) (a) Mehmandoust, M.; Marazano, C.; Das, B. C. *J. Chem. Soc., Chem. Commun.* **1989**, 1185.
(b) Comins, D. L.; Goehring, R. R.; Joseph, S. P.; O'Connor, S. *J. Org. Chem.* **1990**, *55*, 2574.
(c) Comins, D. L.; Joseph, S. P.; Goehring, R. R. *J. Am. Chem. Soc.* **1994**, *116*, 4719.
(d) Comins, D. L.; Guerra-Weltzien, G. *Tetrahedron Lett.* **1996**, *37*, 3807.
(e) Comins, D. L.; Joseph, S. P. *Adv. Nitrogen Heterocycl.* **1996**, *2*, 251.
(f) Comins, D. L.; Dehghani, A. *J. Org. Chem.* **1995**, *60*, 794.
- (6) (a) Danishefsky, S. *J. Am. Chem. Soc.* **1974**, *96*, 7807.
(b) Danishefsky, S.; Langer, M. E.; Vogel, C. *Tetrahedron Lett.* **1985**, *26*, 5983.
- (7) (a) Kunz, H.; Pfrengle, W. *Angew. Chem.* **1989**, *101*, 1041; *Angew. Chem. Int. Ed. Engl.* **1989**, *28*, 1067.
(b) Pfrengle, W.; Kunz, H. *J. Org. Chem.* **1989**, *54*, 4261.
(c) H. Waldmann, H.; Braun, M.; Dräger, M. *Angew. Chem.* **1990**, *102*, 1445; *Angew. Chem. Int. Ed. Engl.* **1990**, *29*, 1468.
(d) Hattori, K.; Yamamoto, H. *Synlett* **1993**, 129.
(e) Ishihara, K.; Miyata, M.; Hattori, K.; Tada, T.; Yamamoto, H. *J. Am. Chem. Soc.* **1994**, *116*, 10520.
(f) McFarlane, A. K.; Thomas, G.; Whiting, A. *J. Chem. Soc. Perkin Trans. 1* **1995**, 2803.
- (8) Kündig, E. P.; Xu, L. H.; Romanes, P.; Bernadinelli, G. *Synlett* **1996**, 270.
- (9) (a) Tallent, W. H.; Horning, H. C. *J. Am. Chem. Soc.* **1956**, *78*, 4467.
(b) see also *Beilstein*; S EIII/IV, Vol. 20, p 1611.
- (10) Craig, J. C.; Pinder, A. R. *J. Org. Chem.* **1971**, *36*, 3648.
- (11) Kunz, H.; Sager, W.; Pfrengle, W.; Schanzenbach, D. *Tetrahedron Lett.* **1988**, *29*, 4397.
- (12) Kunz, H.; Pfrengle, W. *J. Am. Chem. Soc.* **1988**, *110*, 651.
- (13) Laschat, S.; Kunz, H. *J. Org. Chem.* **1991**, *56*, 5883, and references cited therein.
- (14) Hannon, S. J.; Kundu, N. G.; Hertzberg, R. P.; Bhatt, R. S.; Heidelberger, C. *Tetrahedron Lett.* **1980**, *21*, 1105.
- (15) Späth, E.; Keszler, F. *Ber. Dtsch. Chem. Ges.* **1937**, *70*, 704.
- (16) Comins, D. L.; Morgan, L. A. *Tetrahedron Lett.* **1991**, *32*, 5919.
- (17) Corey, E. J.; Boaz, N. W. *Tetrahedron Lett.* **1985**, *26*, 6019.
- (18) Maruyama, K.; Yamamoto, Y. *J. Am. Chem. Soc.* **1977**, *99*, 8068.
- (19) (a) Takahata, H.; Bandoh, H.; Hanayama, M.; Momose, T. *Tetrahedron Asymm.* **1992**, *3*, 607.
(b) Higashiyama, K.; Nakahata, N.; Takahashi, H. *Heterocycles* **1992**, *33*, 17.
(c) Lu, Z.-H.; Zhou, W.-S. *J. Chem. Soc., Perkin Trans.* **1993**, 593.
- (20) Aronstam, R. S.; Daly, S. W.; Spande, T. F.; Narayanan, T. K.; Albuquerque, E. X. *Neurochem. Res.* **1986**, *11*, 1227.
- (21) (a) Polniaszek, R. P.; Belmont, S. E. *J. Org. Chem.* **1990**, *55*, 4688.

- (22) (a) Jefford, C.W.; Tang, Q.; Zaslona, A. *J. Am. Chem. Soc.* **1991**, *113*, 3513.
(b) Fleurant, A.; Saliou, C.; Célerier, J.P.; Platzer, N.; VuMoc, T.; Lhommet, G. *J. Heterocycl. Chem.* **1995**, *32*, 255, and references cited therein.
- (23) Appel, R. *Angew. Chem.* **1975**, *87*, 863; *Angew. Chem. Int. Ed. Engl.* **1975**, *14*, 801.
- (24) (a) Stoilova, V.; Trifonov, L.S.; Orahovats, A.S. *Synthesis* **1979**, 105.
(b) Mulzer, J.; Dehmlow, H.; Buschmann, J.; Luger, P. *J. Org. Chem.* **1992**, *57*, 3194.
- (25) (a) Kunz, H.; Pfrengle, W.; Sager, W. *Tetrahedron Lett.* **1989**, *30*, 4109.
(b) Kunz, H.; Hebrault, D.; publication in preparation.
- (26) Kunz, H.; Sager, W.; Schanzenbach, D.; Decker, M. *Liebigs Ann. Chem.* **1991**, 649.
- (27) Altomare, A.; Cascarano, G.; Giacovazzo, C.; Guagliardi, A.; Burla, M.C.; Polidori, G.; Camalli, M. *J. Appl. Cryst.* **1994**, *27*, 435.
- (28) Sheldrick, G.M. SHELXL93: Program for Crystal Structure Refinement, Universität Göttingen, Germany, 1993.
- (29) Flack, H.D. *Acta Cryst.* **1983**, *A39*, 876.
- (30) Kiguchi, T.; Nakazono, Y.; Kotera, S.; Ninomiya, I.; Naito, T. *Heterocycles* **1990**, *31*, 1525.
- (31) Hill, R.K.; Yuri, T. *Tetrahedron* **1977**, *33*, 1569.
- (32) Ryckman, D.M.; Stevens, R.V. *J. Org. Chem.* **1987**, *52*, 4274.
- (33) For reviews on domino and cascade reactions, see:
(a) Tietze, L.F.; Beifuss, U. *Angew. Chem.* **1993**, *105*, 137; *Angew. Chem. Intl. Ed. Engl.* **1993**, *32*, 131.
(b) Tietze, L.F. *Chem. Rev.* **1996**, *96*, 115.
- (34) Further details of the crystal structure analysis are available on request from the Fachinformationszentrum Karlsruhe GmbH, D-76344 Eggenstein-Leopoldshafen (Germany), on quoting the deposit number CSD-406753, the names of the authors and journal citation.